AbCellera Biologics Inc.

ABCLNASDAQHealthcare● Active

$5.42

$-0.20(-3.56%)

Market Cap$1.7B

P/E Ratio—

52W High$6.79

52W Low$2.33

Avg Volume5.9M

Open$5.86

Beta1.18

PE Ratio Market Cap Forecast

AbCellera Biologics Inc. (ABCL) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

abcl · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for AbCellera Biologics Inc. (ABCL) measures how much investors pay for each dollar of the company's trailing earnings. ABCL's current PE ratio of N/A is calculated by dividing its stock price of $5.42 by its TTM earnings per share of -$0.47.

N/A

P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E

N/A

FY2027 est. EPS $-0.64

Based on 4 analysts

EPS (TTM)

-$0.47

TTM · diluted EPS

PEG Ratio

-0.73

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · AbCellera Biologics Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2018 – 2025 · Annual

PE Ratio (TTM)

5Y Avg 44.9x

EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

Historical PE Range

Past 3 fiscal years · Front-end computed

Average

44.8x

3-yr mean

Median

25.7x

3-yr midpoint

Minimum

18.2x

Lowest year

Maximum

90.6x

Highest year

18.2x
MinQ1 · 25%25.7x
MedianQ3 · 75%90.6x
Max

Historically Low

At N/A, ABCL's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.

0th percentileHigher than 0 of 3 historical fiscal year readings

Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
AbCellera Biologics Inc.You ABCL	$1.7B	N/A	—	-$0.47
Biohaven Ltd. BHVN	$1.2B	N/A	—	-$6.86
Celldex Therapeutics, Inc. CLDX	$1.9B	N/A	—	-$3.89
Immunome, Inc. IMNM	$1.8B	N/A	—	-$2.43
Janux Therapeutics, Inc. JANX	$824M	N/A	—	-$1.83
Nuvation Bio Inc. NUVB	$1.7B	N/A	—	-$0.60
Pharvaris N.V. PHVS	$2.2B	N/A	—	-$2.97

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years

Fiscal Year End	PE Ratio	EPS (TTM)	YoY Change
2025-12-31Latest FY2025	—	$-0.49	—
2024-12-31 FY2024	—	$-0.55	—
2023-12-31 FY2023	—	$-0.51	—
2022-12-31 FY2022	18.22x	$0.56	-29.1%
2021-12-31 FY2021	25.70x	$0.56	-71.6%
2020-12-31 FY2020	90.63x	$0.44	—
2019-12-31 FY2019	—	$-0.01	—
2018-12-31 FY2018	—	$0.00	—

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

PE Ratio = Stock Price ÷ EPS (TTM)

= $5.42 ÷ -$0.47 = N/A

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

ABCL pe ratio · 6 questions

ABCL's current PE ratio is N/A as of 2026-06-08, based on a stock price of $5.42 and TTM EPS of -$0.47. Data sourced from Financial Modeling Prep via ABCL's SEC 10-K and 10-Q filings.

ABCL PE ratioWhat is ABCL PE ratioCurrent PE ratio of ABCLABCL PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · AbCellera Biologics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08